Avalo Therapeutics, Inc. (DE:C6K0)
NASDAQ:C6K0
C6K0 Stock Chart & Stats
€12.06
-€0.35(-4.70%)
At close: 4:00 PM EST
€12.06
-€0.35(-4.70%)
Day’s Range― - ―
52-Week Range€3.39 - €19.32
Previous CloseN/A
Volume0.00
Average Volume (3M)5.00
Market Cap
€631.74M
Enterprise Value€157.48M
Total Cash (Recent Filing)€81.99M
Total Debt (Recent Filing)€2.33M
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Jul 30, 2026EPS Estimate
-0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.83
Shares Outstanding52,565,570
10 Day Avg. Volume0
30 Day Avg. Volume5
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)2.93
Price to Sales (P/S)4125.96
P/FCF Ratio-4.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€40.50Price Target Upside235.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.71
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Positive Phase 2 DataRobust Phase 2 topline results materially strengthen Avalo's clinical thesis for abdakibart. Statistically significant efficacy and placebo-comparable safety across prior biologic exposure support a differentiated registrational program, improving odds of a viable late-stage asset and long-term commercial opportunity if replicated.
Substantial Capital RaiseA ~$405m equity/warrant raise materially extends funding runway to complete Phase 3 development and topline readout, reducing near-term financing risk. This strengthens the firm's ability to execute clinical plans and deliver value-driving milestones without immediate cash constraints common to clinical-stage biotechs.
Low Financial LeverageZero debt and low leverage lower fixed financial obligations, giving management flexibility to prioritize R&D spending and manage timing of external financings. This reduces insolvency risk during multi-year clinical programs and preserves strategic optionality to negotiate partnerships or staged financings.
Bears Say
High Cash BurnSustained negative operating and free cash flow (~$59.7M TTM) means the business remains dependent on external capital to fund trials. Persistent burn forces recurring financings, constrains long-term planning, and raises execution risk if capital markets tighten or trial costs exceed expectations.
Minimal And Declining Revenue BaseRevenue has effectively collapsed to near zero, reflecting no commercialized products and limited non-dilutive funding. This makes the company binary on clinical success: without predictable product revenues, growth and sustainability depend on successful trials, partnerships, or continued capital raises.
Dilution Risk From Large OfferingThe scale of the equity and warrant issuance materially dilutes existing shareholders and can pressure per-share metrics over the medium term. While proceeds fund trials, recurring or large dilutive financings remain likely given burn, which can erode shareholder value and affect long-term returns if pipeline milestones lag.
Avalo Therapeutics News
C6K0 FAQ
What was Avalo Therapeutics, Inc.’s price range in the past 12 months?
Avalo Therapeutics, Inc. lowest stock price was €3.38 and its highest was €19.32 in the past 12 months.
What is Avalo Therapeutics, Inc.’s market cap?
Avalo Therapeutics, Inc.’s market cap is €631.74M.
When is Avalo Therapeutics, Inc.’s upcoming earnings report date?
Avalo Therapeutics, Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 57 days.
How were Avalo Therapeutics, Inc.’s earnings last quarter?
Avalo Therapeutics, Inc. released its earnings results on May 13, 2026. The company reported -€0.843 earnings per share for the quarter, beating the consensus estimate of -€0.882 by €0.039.
Is Avalo Therapeutics, Inc. overvalued?
According to Wall Street analysts Avalo Therapeutics, Inc.’s price is currently Undervalued.
Does Avalo Therapeutics, Inc. pay dividends?
Avalo Therapeutics, Inc. does not currently pay dividends.
What is Avalo Therapeutics, Inc.’s EPS estimate?
Avalo Therapeutics, Inc.’s EPS estimate is -0.54.
How many shares outstanding does Avalo Therapeutics, Inc. have?
Avalo Therapeutics, Inc. has 52,565,570 shares outstanding.
What happened to Avalo Therapeutics, Inc.’s price movement after its last earnings report?
Avalo Therapeutics, Inc. reported an EPS of -€0.843 in its last earnings report, beating expectations of -€0.882. Following the earnings report the stock price went down -1.294%.
Which hedge fund is a major shareholder of Avalo Therapeutics, Inc.?
Currently, no hedge funds are holding shares in DE:C6K0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Avalo Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€40.50 (235.83% Upside)
€40.50 (235.83% Upside)
Blogger Sentiment
Bullish
DE:C6K0 Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €353.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
220.91%
12-Months-Change
Fundamentals
Return on Equity
-97.55%
Trailing 12-Months
Asset Growth
-27.89%
Trailing 12-Months
Company Description
Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
C6K0 Stock 12 Month Forecast
Average Price Target
€40.50
▲(235.83% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Forte Biosciences
―
Milestone Pharmaceuticals
―
Elicio Therapeutics
―
Fractyl Health, Inc.
―
Options Prices
Currently, No data available
---